ArticleAmerican journal of men's health2017
Metabolic Syndrome Patients Have Lower Levels of Adropin When Compared With Healthy Overweight/Obese and Lean Subjects.
Article in American journal of men's health, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03724825 (Correlation of Serum Adropin to Testosterone and Adiponectin in Obese Men), which is not on this map. Cited by 37 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Correlation of Serum Adropin to Testosterone and Adiponectin in Obese Men
Who cites it
37 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Circulating levels of adropin and diabetes: a systematic review and meta-analysis of observational studies.BMC endocrine disorders · 2023Pooled it
- Circulating levels of adropin and overweight/obesity: a systematic review and meta-analysis of observational studies.Hormones (Athens, Greece) · 2022Pooled it
- Trial
- Adropin signaling pathways in metabolic and non-metabolic disorders.Molecular biology reports · 2026Review
- Association of diabetes risk reduction diet (DRRD) score with metabolic health, brain-derived neurotrophic factor and adropin in Iranian adults.Nutrition journal · 2025Article
- A Potential Role of Adropin in Inflammatory Rheumatic Diseases-What Do We Know So Far?Biomedicines · 2025Review
- An Increase of Adropin Can Predict Depression Improvement.Nutrients · 2025Article
- Serum adropin is unaltered in adolescents with histology-confirmed steatotic liver disease.Journal of pediatric gastroenterology and nutrition · 2025Article
- Irisin and adropin decrease in preobese or obese individuals with nonalcoholic fatty liver disease.Turkish journal of medical sciences · 2025Article
- Ultra-processed foods intake in relation to metabolic health status, serum brain-derived neurotrophic factor and adropin levels in adults.Nutrition journal · 2024Article
- Low Levels of Adropin Predict Adverse Clinical Outcomes in Outpatients with Newly Diagnosed Prediabetes after Acute Myocardial Infarction.Biomedicines · 2024Article
- Insulin resistance-related circulating predictive markers in the metabolic syndrome: a systematic review in the Iranian population.Journal of diabetes and metabolic disorders · 2024Review
- Dietary Phytochemical Index in Relation to Metabolic Health Status, Serum Adropin, and Brain-Derived Neurotrophic Factor Levels in Adults.Current developments in nutrition · 2024Article
- Nutrient patterns in relation to metabolic health status and serum levels of brain-derived neurotrophic factor (BDNF) and adropin in adults.Scientific reports · 2024Article
- Serum Adropin Levels Are Elevated in Patients With Hyperthyroidism.International journal of endocrinology · 2024Article
- Clinical Significance of Adropin and Afamin in Evaluating Renal Function and Cardiovascular Health in the Presence of CKD-MBD Biomarkers in Chronic Kidney Disease.Diagnostics (Basel, Switzerland) · 2023Article
- Serum Adropin Levels and Body Mass Composition in Kidney Transplant Recipients-Are There Sex Differences?Diagnostics (Basel, Switzerland) · 2023Article
- Friend or foe for obesity: How hepatokines remodel adipose tissues and translational perspective.Genes & diseases · 2023Review
- Biomarkers of Osteoarthritis-A Narrative Review on Causal Links with Metabolic Syndrome.Life (Basel, Switzerland) · 2023Review
- Serum Levels of Adropin Improve the Predictability of MELD and Child-Pugh Score in Cirrhosis: Results of Proof-of-Concept Clinical Trial.Transplant international : official journal of the European Society for Organ Transplantation · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Metabolic syndrome (MetS), a cluster of cardiometabolic risk factors, is a challenging public health issue. The aim of current study was to test the hypothesis that concentrations of plasma adropin and leptin differ between patients with MetS and comparable age- and sex-matched control groups. This case-control study involved 153 subjects (51 per group). The study group included obese subjects with MetS and the two control groups included weight-matched subjects without MetS ("healthy": obese) and normal weight subjects without MetS. Body composition parameters were measured using bioelectrical impedance analysis. Plasma levels of adropin, leptin, and their ratio were measured. Leptin was significantly different between obese patients with/without MetS groups and normal weight subjects. Patients with MetS had higher levels of leptin (14 ± 12.4) compared with those without MetS (11.2 ± 9.3 vs. 7 ± 7.1 obese and normal weight without MetS, respectively; p = .002). Compared with healthy obese and normal weight subjects, MetS subjects had lower levels of plasma adropin ( p < .001) and a lower plasma adropin to leptin ratio ( p < .001), which remained significant when adjusted for body fat mass by analysis of covariance ( p < .001). This study demonstrates low levels of adropin are correlated with MetS and hence identify it as a potentially protective agent against MetS development. Variation in adropin levels may partly explain the "healthy obese" phenomenon.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.